Alerts

DNA Genotek received the ISM Industrial Award during Targeting Microbiota 2019

International Society of Microbiota (ISM) is honored to announce DNA Genotek as one of three winners of the Industrial Innovation Awards, during the 7th World Congress on Targeting Microbiota 2019, which was held in Krakow, Poland.

 

DNAgenotek sponsor small

DNA Genotek is recognized as a leader worldwide in the production and development of standardized skin microbiome and fecal metabolomics collection methodologies.

Testimonial by Heloise Breton, from DNA Genotek:
"We would like to thank the scientific committee for awarding us the the industrial innovation award. As a company dedicated to developing products to optimize ease of collection and provide superior samples and proven performance, we are so happy to see our value in the industry recognized. This year’s Targeting Microbiota conference consisted of many great talks that captured the role of the microbiome in human and animal systems. The connection between the brain and the gut is a huge development and the work happening in this field will be life changing for neurological diseases such as Alzheimer’s. Skin microbiome is an upcoming topic and of high interest for us as we have been working on a collection device for skin sampling which will launch soon. This is a topic that has many applications as seen in the talks regarding cosmetics, immune function and cutaneous homeostasis. There is so much amazing research happening in Europe and we enjoy being a part of such an innovative scientific community. We hope to see the ISM grow every year and to continue to provide a platform for the future of microbiome research."

DNAGenotek 4

DNAGenotek 2

DNAGenotek 1 

Media center: 
Internternational Society of Microbiota
Contact: microbiota@microbiota-site.com
www.microbiota-site.com

International Society of Microbiota awarded R.E.D. Laboratories during Targeting Microbiota 2019

International Society of Microbiota (ISM) is honored to discern Industrial Innovation Award to R.E.D. Laboratories during the 7th World Congress on Targeting Microbiota 2019, which was held in Krakow, Poland.

blue avatar red laboratories

R.E.D. Laboratories highlighted the high importance of assessing inflammation-related markers in the evaluation of autism spectrum disorders-diagnosed patients.

Testimonial by Dr. Tanja Mijatovic, from R.E.D. Laboratories:
"I really enjoyed the Conference, it was all very well organized and extremely professional.  A great conference to attend for anyone in the microbiome fields. Great for gaining insights into unpublished research and clinical findings, and a significant opportunity to network with enthusiastic colleagues. I came back with valuable insights and fully charged with positive emotions. Huge thanks to the organizers. It was amazing to be awarded. Looking forward to be back next year."

REDLaboratories

Redlaboratories 1

Media center: 
International Society of Microbiota 
Contact: microbiota@microbiota-site.com
www.microbiota-site.com

Industrial Innovation Award was discerned to Sethic Innovation Lab during Targeting Microbiota 2019

The Industrial Innovation Award was discerned to Sethic Innovation Lab during Targeting Microbiota 2019 Congress.

Sethic Innovation Lab


Scientific Committee awarded Sethic Innovation Lab for their innovating cosmetic ingredient OPTIMEALTH(R), presented as a potent ingredient to prevents and reduce skin infections, inflammation and related disorders such as atopic dermatitis, rosacea, psoriasis, and acne.

SethicInnovation

StehicInnovation 

Media center: 
International Society of Microbiota
Contact: microbiota@microbiota-site.com
www.microbiota-site.com

The Poster Contribution Award was discerned to Dr. Agata Chudzik

Targeting Microbiota 2019 Dr. ChudzikThe Poster Contribution Award was discerned to Dr. Agata Chudzik from Medical University of Lublin, Poland, during Targeting Microbiota 2019, which was held in Krakow, Poland, for her poster presentation entitled "Evaluation of neurometabolites level after microbiotic supplementation (Lactobacillus rhumnosus LR-JB1TM) in rat model of chronic unpredictable mild stress".

The study assesses the neurometabolic and behavioral changes after bacterial diet in an animal model of chronic unpredictable mild stress. The results show that JB-1 bacteria diet influenced the stabilization of stress-related neurometabolites in rat brain and prevented to develop anxiety/depressive-like behavior. 

 Testimonial by Dr. Chudzik:
"It was a great pleasure to attend to Targeting Microbiota 2019 Congress. I would like to thank Organizers for the opportunity to present my PhD research and I feel very honoured that Scientific Committee awarded it.Participating in Targeting Microbiota Congress allowed me to hear and discuss the recent advances and challenges in the microbiota research. The outstanding lectures given by experts in the field of human and animal microbiome were very inspiring and enabled a new look at the topics discussed. I have enriched my knowledge about the microbiome-gut-brain axis in detail, which is a particularly exciting issue for me. Moreover congress allowed me to meet people interested in similar issues and every conversation led to  brainstorming and sharing ideas."

Media center:
International Society of Microbiota 
Contact: microbiota@microbiota-site.com
www.microbiota-site.com

The Short Oral Contribution Award was delivered to Dr. Satu Pekkala

Targeting Microbiota 2019 Satu PekkalaDuring the Targeting Microbiota 2019 congress, which was held in Krakow, Poland, the Scientific Committee awarded Dr. Satu Pekkala, from University of Jyvaskyla, Finland, for her Oral Presentation entitled "Targeting Faecalibacterium prausnitzii with prebiotic xylo oligosaccharides prevents from Non-Alcoholic Fatty Liver Disease (NAFLD)"

The study presented by Dr. Pekkala identifies F. prausnitzii as target treat NAFLD and the underlying preventive mechanisms that involve fat oxidation and glucose metabolism. 

Testimonial by Dr. Pekkala
" I am very honored for this award and I congratulate the International of Society of Microbiota by organizing the congress 7th Targeting Microbiota full of excellent presentations. I have always thought that the gut microbiota studies should advance from detecting associations to show mechanistically the biological significance of the detected associations. This is needed to be able to target the microbes to treat different diseases in the future. Therefore, I am thrilled to see the development of the gut microbiota studies from year to year in this congress!

I am currently Academy of Finland Research Fellow at the Faculty of Sport and Health Sciences, University of Jyväskylä, Finland. I am also Adjunct Professor at the Faculty of Medicine, University of Turku, Finland. My research team has discovered that a specific gut bacterium, Faecalibacterium prausnitzii associated with liver fat content in humans. We treated a murine model of fatty liver with this bacterium and found that it was able to prevent the disease. Unfortunately, the potential therapeutic microbes are not always accepted for human use and therefore it is important to find alternative ways to increase their natural abundance in the gut. As I presented in the congress, we found a prebiotic fibre that increased F. prausnitzii in vivo and at the same could prevent fatty liver in rats. We are currently setting up a human study to see whether our findings can be translated to humans."

Media center:
International Society of Microbiota
Contact: microbiota@microbiota-site.com
www.microbiota-site.com